Drug profile · INN
elacestrant hydrochloride
ORSERDU
elacestrant hydrochloride (ORSERDU) is a estrogen receptor alpha degrader. Route of administration: oral. Current US regulatory status: approved.
Drug details — elacestrant hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 1
- Programs
- 3
- Data quality
- 0.84
Quick answer
elacestrant hydrochloride (ORSERDU) is a estrogen receptor alpha degrader. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Estrogen receptor alpha degrader
Primary target: Estrogen receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is elacestrant hydrochloride?
elacestrant hydrochloride (ORSERDU) is a estrogen receptor alpha degrader. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for elacestrant hydrochloride?
ORSERDU is a marketed brand name for elacestrant hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of elacestrant hydrochloride?
elacestrant hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.